NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis early-stage study tests a new drug, BPI-572270, in adults with advanced solid tumors (lung, colorectal, pancreatic) that have specific RAS gene mutations. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 120 participants who …
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 17, 2026 00:58 UTC
-
New hope for advanced lung cancer: JSKN033 enters phase II trial
Disease control Not yet recruitingThis study tests a new drug called JSKN033 in 160 people with advanced non-small cell lung cancer that cannot be cured. The goal is to see if the drug is safe and can shrink tumors. Participants will receive the drug and be monitored for side effects and response.
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 17, 2026 00:44 UTC
-
New drug combo aims to fight advanced cancers
Disease control Not yet recruitingThis study tests a new drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, or ovarian cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants will join thi…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:04 UTC
-
New combo targets lung cancer brain metastases in early trial
Disease control Not yet recruitingThis study tests whether a higher dose of furmonertinib alone works better than a standard dose combined with chemotherapy for people with a specific type of lung cancer (EGFR-mutated) that has spread to the brain. About 60 adults who have not had prior treatment will be enrolled…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC
-
New drug targets Hard-to-Treat lung cancer mutation in major trial
Disease control Not yet recruitingThis study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:05 UTC
-
New combo therapy aims to boost lung cancer control without surgery
Disease control Not yet recruitingThis study tests whether adding Huaier granules to microwave ablation (a heat-based tumor treatment) helps people with early-stage, inoperable lung cancer live longer without the disease getting worse. About 180 adults will be randomly assigned to receive ablation alone or ablati…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE3 • Sponsor: Xin Ye • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and can shrink tumors. About 178 adults with cancers like pancreatic, lung, or colorectal cancer will take…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 05, 2026 12:07 UTC
-
New combo targets tricky lung cancer transformation after standard therapy fails
Disease control Not yet recruitingThis study tests a combination of the targeted drug limertinib plus chemotherapy (carboplatin and etoposide) in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. About 30…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Hunan Province Tumor Hospital • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
Lung cancer patients to test athletic recovery program
Symptom relief Not yet recruitingThis pilot study will enroll 10 people who had surgery for early-stage non-small cell lung cancer. Participants will follow a 6-month athletic training program supervised by a sports scientist. The goal is to see if exercise can improve lung function, fitness, and quality of life…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Symptom relief
Last updated Jun 16, 2026 12:52 UTC
-
Smart wearables aim to boost lung cancer surgery recovery
Knowledge-focused Not yet recruitingThis study tests a new way to help people with non-small cell lung cancer recover after chest surgery. It uses wearable devices and a smartphone app to monitor patients before and after the operation, and guides them through home exercises. The goal is to see if this digital appr…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: NA • Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:07 UTC
-
Can ancient chinese medicine predict lung cancer drug success?
Knowledge-focused Not yet recruitingThis study looks at how Traditional Chinese Medicine (TCM) body patterns, like tongue and pulse readings, relate to how well targeted lung cancer drugs work. About 3000 people with a specific type of lung cancer will be followed for up to 5 years. Researchers will collect TCM inf…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: Guangzhou University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC
-
New blood test could tell who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study aims to create a blood test that predicts whether immunotherapy will work for people with certain cancers, including lung, skin, breast, kidney, and head and neck cancers. Researchers will analyze a type of white blood cell called neutrophils in samples from 600 patien…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Sponsor: OncoHost Ltd. • Aim: Knowledge-focused
Last updated Jun 02, 2026 11:57 UTC